| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 141,076 | 138,514 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 17,906 | 1,830 |
| Cash and cash equivalents at beginning of period | 97,381 | - |
| Cash and cash equivalents at end of period | 115,287 | - |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)